Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

24.02
-0.2700-1.11%
Pre-market: 24.160.1400+0.58%07:31 EDT
Volume:1.13M
Turnover:27.27M
Market Cap:2.72B
PE:-6.95
High:24.39
Open:24.35
Low:24.00
Close:24.29
52wk High:34.29
52wk Low:13.18
Shares:113.29M
Float Shares:108.00M
Volume Ratio:0.73
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4579
EPS(LYR):-3.3245
ROE:-65.74%
ROA:-30.16%
PB:4.82
PE(LYR):-7.23

Loading ...

Viridian Therapeutics Shares Down 33.5% Premarket After Co Reports Late‑Stage Trial Data for Its Thyroid Eye Disease Drug

THOMSON REUTERS
·
Mar 30

Viridian's thyroid eye disease drug succeeds in late‑stage trial

Reuters
·
Mar 30

Viridian announces results from elegrobart REVEAL-1 phase 3 trial

TIPRANKS
·
Mar 30

Viridian says elegrobart hits primary endpoint in Phase 3 REVEAL-1 thyroid eye disease trial

Reuters
·
Mar 30

Viridian Therapeutics Inc - Elegrobart Generally Well Tolerated With Low Rates of Hearing Impairment

THOMSON REUTERS
·
Mar 30

Viridian Therapeutics Inc - Reveal-1 Trial Meets Primary Endpoint With Statistically Significant Q4w Proptosis Responder Rate

THOMSON REUTERS
·
Mar 30

Viridian Therapeutics Announces Positive Topline Results From Elegrobart Phase 3 Reveal‑1 Clinical Trial in Active Thyroid Eye Disease

THOMSON REUTERS
·
Mar 30

Wells Fargo Sticks to Their Hold Rating for Viridian Therapeutics (VRDN)

TIPRANKS
·
Mar 02

Truist Financial Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)

TIPRANKS
·
Feb 27

Analysts’ Top Healthcare Picks: Heron Therapeutics (HRTX), Viridian Therapeutics (VRDN)

TIPRANKS
·
Feb 27

Viridian Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 27

Viridian Therapeutics Q4 revenue misses analyst expectations

Reuters
·
Feb 26

Viridian posts FY 2025 net loss of USD 342.6 million

Reuters
·
Feb 26

BRIEF-Viridian Therapeutics Q4 Revenue USD 132 Thousand Vs. IBES Estimate USD 12.7 Million

Reuters
·
Feb 26

Viridian Therapeutics Q4 EPS USD -1.08 VS. Ibes Estimate USD -1.07

THOMSON REUTERS
·
Feb 26

Viridian Therapeutics: IF Both Veligrotug, Elegrobart Are Approved, Co Expects Current Business Plans to Be Funded Through Profitability

THOMSON REUTERS
·
Feb 26

Viridian Therapeutics Q4 Revenue USD 132 Thousand VS. Ibes Estimate USD 12.7 Million

THOMSON REUTERS
·
Feb 26

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Feb 26